Aveta Biomics to Present at the Upcoming 2025 ESMO Congress
PDF Version ESMO data illuminate APG-157’s immune-modulating mechanism in Head and Neck Cancer ahead of the upcoming Phase 3 trial and its broad therapeutic potential BEDFORD, MA, UNITED STATES, October 13, 2025 /EINPresswire.com/ — Aveta Biomics, a clinical-stage biotechnology company developing first-in-class drugs that reprogram the immune system to fight cancer, today announced the poster […]
Aveta Biomics to Present at the Upcoming 2025 ESMO Congress Read More »
